Publications by authors named "Peter Venner"

Claim this Profile
H
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience.
Hanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, Tina Cheng, Michael Chu, Christopher P Venner, Peter Venner

Can Urol Assoc J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada.
Catalina Vasquez, Michael Kolinsky, Rume Djebah, Maxwell Uhlich, Bryan Donnelly, Peter Venner

BMJ Open· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting.
Jordan Hill, Mike Paulden, Christopher McCabe, Scott A North, Peter Venner

Can J Urol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
Georg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, Denis Soulieres, D Scott Ernst, Peter M Venner

Eur J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma.
Seyyed Mohammad Reza Kazemi-Bajestani, Harald Becher, Peter Venner, Scott North, Vickie Baracos

Clin Nutr· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.
M Neil Reaume, Naveen S Basappa, Lori Wood, Anil Kapoor, Georg A Bjarnason, Peter Venner

Can Urol Assoc J· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.
Aly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, Lori Wood, Austin Kalirai, Peter Venner

Can Urol Assoc J· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avascular Necrosis of the Femoral Head After Palliative Radiotherapy in Metastatic Prostate Cancer: Absence of a Dose Threshold?
Alia M Daoud, Mack Hudson, Kenneth G Magnus, Fleur Huang, Brita L Danielson, Peter Venner

Cureus· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.
Scott A North, , Naveen Basappa, Joan Basiuk, Georg Bjarnason, Peter Venner

Can Urol Assoc J· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.
Quincy Siu-Chung Chu, Randeep Sangha, Jennifer Spratlin, Larissa J Vos, John R Mackey, Peter Venner

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Peter M Venner

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.
Faraj El-Gehani, Scott North, Sunita Ghosh, Peter Venner

Can Urol Assoc J· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
Suzanne Richter, J Dean Ruether, Lori Wood, Christina Canil, Patricia Moretto, Peter Venner

Can Urol Assoc J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma.
Lori Wood, Georg A Bjarnason, Peter C Black, Ilias Cagiannos, Daniel Yick Chin Heng, Peter Venner

J Oncol Pract· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent versus continuous androgen deprivation in prostate cancer.
Maha Hussain, Catherine M Tangen, Donna L Berry, Celestia S Higano, E David Crawford, Peter M Venner

N Engl J Med· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).
G Michael Allan, Michael P Chetner, Bryan J Donnelly, Neil A Hagen, David Ross, Peter Venner

Can Urol Assoc J· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Howard I Scher, Xiaoyu Jia, Kim Chi, Ronald de Wit, William R Berry, Peter M Venner

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline.
Brendan J W Miles, Adrian S Fairey, Michael Eliasziw, Eric P Estey, Peter Venner

Can Urol Assoc J· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian consensus guidelines for the management of testicular germ cell cancer.
Lori Wood, Christian Kollmannsberger, Michael Jewett, Peter Chung, Sebastian Hotte, Peter Venner

Can Urol Assoc J· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Sami Antoun, Laura Birdsell, Michael B Sawyer, Peter Venner, Bernard Escudier

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytoreductive nephrectomy: a treatment of the past.
Peter Venner

Can Urol Assoc J· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Daniel Y C Heng, Wanling Xie, Meredith M Regan, Mark A Warren, Ali Reza Golshayan, Peter Venner

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer.
Mikael Hanninen, Peter Venner, Scott North

Can Urol Assoc J· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of indirect cauda equina syndrome from metastatic prostate cancer.
Shilo Lefresne, Alysa Fairchild, Aalo Bistritz, Peter Venner, Don Yee

Can Urol Assoc J· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.
Mark Warren, Peter M Venner, Scott North, Tina Cheng, Chris Venner, Allison A Venner

Can Urol Assoc J· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis